Bevacizumab use for recurrent high-grade glioma at McGill University Hospital

Canadian Journal of Neurological Sciences

Volumn 40, Issue 2, 2013, Pages 241-246

  Sahebjam, Solmaz ^a   Garoufalis, Evgenia ^b   Guiot, Marie Christine ^c   Muanza, Thierry ^d   Del Maestro, Rolando ^e   Petrecca, Kevin ^e   Sharma, Rajesh ^b   Kavan, Petr ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; EVEROLIMUS; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE;

ADULT; ANAPLASTIC GLIOMA; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLIOBLASTOMA; GLIOMA; HUMAN; LUNG EMBOLISM; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 84874274485     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100013809     Document Type: Article

References (35)

1. adamson C, Kanu OO, Mehta aI, et al. Glioblastoma multiforme: A review of where we have been and where we are going. Expert Opin Investig Drugs. 2009;18(8):1061-83
2. Stupp R, Mason WP, van den bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-96
3. Curran Jr WJ, Scott Cb, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704-10
4. Kargiotis O, Rao JS, Kyritsis aP. Mechanisms of angiogenesis in gliomas. J Neurooncol. 2006;78(3):281-93
5. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev. 2004;25(4):581-611
6. Hicklin DJ, Ellis lM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011-127
7. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671-80
8. Yang JC, Haworth l, Sherry RM, et al. a randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349 (5):427-34
9. Hurwitz H, Fehrenbacher l, Novotny W, et al. bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50
11. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-76
12. Mathieu V, De Néve N, le Mercier M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008;10(12):1383-92
13. lee CG, Heijn M, di Tomaso E, et al. anti-vascular endothelial growth factor treatment augments tumour radiation response under normoxic or hypoxic conditions. Cancer Res. 2000;60 (19):5565-70
14. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007a;13(4):1253-9
15. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007b;25(30):4722-9
16. Norden aD, Young GS, Setayesh K, et al. bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-87
17. Kreisl TN, Kim l, Moore K, et al. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-5
18. Friedman HS, Prados MD, Wen PY, et al. bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-40
19. Cohen MH, Shen Yl, Keegan P, Pazdur R. FDa drug approval summary: Bevacizumab (avastin) as treatment of recurrent glioblastoma multiforme. Oncologist. 2009;14(11):1131-8
20. Wen PY, Macdonald DR, Reardon Da, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-72
21. Theeler bJ, Groves MD. High-grade gliomas. Curr Treat Options Neurol. 2011;13(4):386-99
22. Yung WK, albright RE, Olson J, et al. a phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. br J Cancer. 2000;83(5):588-93
23. Wong ET, Gautam S, Malchow C, lun M, Pan E, brem S. bevacizumab for recurrent glioblastoma multiforme: A metaanalysis. J Natl Compr Canc Netw. 2011;9(4):403-7
24. Poulsen HS, Grunnet K, Sorensen M, et al. bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. acta Oncol. 2009;48(1):52-8
25. Soffietti R, Ruda R, Trevisan E, et al. Phase II study of bevacizumab and nitrosourea in patients with recurrent malignant glioma: A multicenter Italian study. J Clin Oncol. 2009;27(suppl; abstr 2012
26. Reardon Da, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: A phase II study. br J Cancer. 2009; 101(12):1986-94
27. Guiu S, Taillibert S, Chinot O, et al. bevacizumab/irinotecan. an active treatment for recurrent high grade gliomas: Preliminary results of an aNOCEF Multicenter Study. Rev Neurol (Paris). 2008;164(6-7):588-94
28. Gilbert MR, Wang M, aldape K, et al. RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GbM). J Clin Oncol. 2009;27(suppl; abstr 2011
29. Sathornsumetee S, Desjardins A, Vredenburgh JJ, et al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12(12):1300-10
30. Verhoeff JJ, lavini C, van linde ME, et al. bevacizumab and doseIntense temozolomide in recurrent high-grade glioma. ann Oncol. 2010;21(8):1723-7
31. Elandt K, Preusser M, Hassler M, et al. Treatment with bevacizumab and liposomal doxorubicin for recurrent highgrade gliomas (HGGs). J Clin Oncol. 2010;28(suppl; abstr e12522
32. Calabrich A, azevedo FC, Saad ED, et al. The feasibility and reallife effectiveness of the combination of chemotherapy (CT) and bevacizumab (bev) in the treatment of high-grade gliomas (HGG) in a private community oncology center. J Clin Oncol. 2010;28(suppl; abstr e12552
33. Gallardo Martin E, areses Manrique MC, anido Herranz U, et al. Efficacy, toxicity, and pattern of response and progression in patients with high-grade gliomas treated with bevacizumab and irinotecan: Experience in one center. J Clin Oncol. 2010;28 (suppl; abstr e12553
34. Vredenburgh JJ, Coughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the bRaIN study. Oncologist. 2010;15(12): 1329-34
35. Henriksson R, asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: A review. J Neurooncol. 2011;104(3): 639-46